Maria da Glória Correia da Silva Queiroz

Prof. Dr. Maria da Glória Correia da Silva Queiroz

Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2009 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JNJosé Neves
José Neves
CMCarla Matos
Carla Matos
CMCarla Moutinho
Carla Moutinho
Maria da Glória Correia da Silva QueirozMaria da Glória Correia da Silva Queiroz
Maria da Glória Correia da Silva Queiroz
Lígia Rebelo GomesLígia Rebelo Gomes
Lígia Rebelo Gomes

1 April 1997 in Neuroscience
Verified
Journal Article
Closed access
Maria da Glória Correia da Silva QueirozMaria da Glória Correia da Silva Queiroz
Maria da Glória Correia da Silva Queiroz
PGP.J Gebicke-Haerter
P.J Gebicke-Haerter
ASA Schobert
A Schobert
KSK Starke
K Starke
IKI von Kügelgen
I von Kügelgen

1 July 1999 in Neuroscience
Verified
Journal Article
Closed access
Maria da Glória Correia da Silva QueirozMaria da Glória Correia da Silva Queiroz
Maria da Glória Correia da Silva Queiroz
DMD.K. Meyer
D.K. Meyer
AMA. Meyer
A. Meyer
KSK. Starke
K. Starke
IKI. von Kügelgen
I. von Kügelgen

3 September 2014 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
Clara QuintasClara Quintas
Clara Quintas
DPDiana Pinho
Diana Pinho
Clara PereiraClara Pereira
Clara Pereira
Lucília SaraivaLucília Saraiva
Lucília Saraiva
Jorge GonçalvesJorge Gonçalves
Jorge Gonçalves
Maria da Glória Correia da Silva QueirozMaria da Glória Correia da Silva Queiroz
Maria da Glória Correia da Silva Queiroz
During cerebral inflammation uracil nucleotides leak to the extracellular medium and activate glial pyrimidine receptors contributing to the development of a reactive phenotype. Chronically activated microglia acquire an anti-inflammatory phenotype that favors neuronal differentiation, but the impact of these microglia on astrogliosis is unknown. We investigated the contribution of pyrimidine receptors to microglia-astrocyte signaling in a chronic model of inflammation and its impact on astrogliosis. Co-cultures of astrocytes and microglia were chronically treated with lipopolysaccharide (LPS) and incubated with uracil nucleotides for 48 h. The effect of nucleotides was evaluated in methyl-[3H]-thymidine incorporation. Western blot and immunofluorescence was performed to detect the expression of P2Y6 receptors and the inducible form of nitric oxide synthase (iNOS). Nitric oxide (NO) release was quantified through Griess reaction. Cell death was also investigated by the LDH assay and by the TUNEL assay or Hoechst 33258 staining. UTP, UDP (0.001 to 1 mM) or PSB 0474 (0.01 to 10 μM) inhibited cell proliferation up to 43 ± 2% (n = 10, P <0.05), an effect prevented by the selective P2Y6 receptor antagonist MRS 2578 (1 μM). UTP was rapidly metabolized into UDP, which had a longer half-life. The inhibitory effect of UDP (1 mM) was abolished by phospholipase C (PLC), protein kinase C (PKC) and nitric oxide synthase (NOS) inhibitors. Both UDP (1 mM) and PSB 0474 (10 μM) increased NO release up to 199 ± 20% (n = 4, P <0.05), an effect dependent on P2Y6 receptors-PLC-PKC pathway activation, indicating that this pathway mediates NO release. Western blot and immunocytochemistry analysis indicated that P2Y6 receptors were expressed in the cultures being mainly localized in microglia. Moreover, the expression of iNOS was mainly observed in microglia and was upregulated by UDP (1 mM) or PSB 0474 (10 μM). UDP-mediated NO release induced apoptosis in astrocytes, but not in microglia. In LPS treated co-cultures of astrocytes and microglia, UTP is rapidly converted into UDP, which activates P2Y6 receptors inducing the release of NO by microglia that causes astrocyte apoptosis, thus controlling their rate of proliferation and preventing an excessive astrogliosis.

1 November 2003 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
Maria da Glória Correia da Silva QueirozMaria da Glória Correia da Silva Queiroz
Maria da Glória Correia da Silva Queiroz
CTCarlos Talaia
Carlos Talaia
Jorge GonçalvesJorge Gonçalves
Jorge Gonçalves
The role of ATP on the modulation of noradrenaline release elicited by electrical stimulation (100 pulses/8 Hz) was studied in the prostatic portion of rat vas deferens preincubated with [3H]noradrenaline. In the presence of P1 antagonists, the nucleotides 2-methylthioadenosine-5′-triphosphate (2-MeSATP), 2-methylthioadenosine 5′-diphosphate (2-MeSADP), ADP, and ATP decreased electrically evoked tritium overflow up to 44%, with the following order of potency: 2-MeSATP > 2-MeSADP > ADP ≥ ATP. The P2Y antagonists reactive blue 2 (RB2) and 2-methylthioadenosine 5′-monophosphate (2-MeSAMP) increased, whereas the P2X antagonist pyridoxal-5′-phosphate-6-(2′-naphthylazo-6′-nitro-4′,8′-disulfonate) (PPNDS) decreased evoked tritium overflow. The inhibitory effect of 2-MeSATP was antagonized by RB2 (10 μM) and by 2-MeSAMP (10 μM) but not by the selective P2Y1 receptor antagonist 2′-deoxy-N6-methyladenosine 3′,5′-bisphosphate (MRS 2179; 10 μM). When, besides P1 receptors, inhibitory P2Y receptors were blocked with RB2, α,β-methyleneadenosine 5′-triphosphate (α,β-meATP), β,γ-imidoadenosine 5′-triphosphate (β,γ-imidoATP), β,γ-methyleneadenosine 5′-triphosphate (β,γ-meATP), 2-MeSATP, and ATP enhanced tritium overflow up to 140%, with the following order of potency: α,β-meATP > 2-MeSATP = ATP = β,γ-meATP ≥ β,γ-imidoATP. The facilitatory effects of α,β-MeATP and β,γ-imidoATP were prevented by PPNDS. Under the same conditions, apyrase attenuated, whereas the ectonucleotidase inhibitor 6-N,N-diethyl-d-β,γ-dibromomethylene 5′-triphosphate enhanced tritium overflow, an effect that was prevented by PPNDS. In the prostatic portion of the rat vas deferens, endogenous ATP exerts a dual and opposite modulation of noradrenaline release: an inhibition through activation of P2Y receptors with a pharmacological profile similar to that of the P2Y12 and P2Y13 receptors and a facilitation through activation of P2X receptors with a pharmacological profile similar to that of P2X1 and P2X3, or PX2/P2X3 receptors.

1 January 1996 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
Jorge GonçalvesJorge Gonçalves
Jorge Gonçalves
Maria da Glória Correia da Silva QueirozMaria da Glória Correia da Silva Queiroz
Maria da Glória Correia da Silva Queiroz
1 The effects of analogues of adenosine and ATP on noradrenaline release elicited by electrical stimulation (5 Hz, 2700 pulses) were studied in superfused preparations of rat tail artery. The effects of purinoceptor antagonists, of adenosine deaminase and of adenosine uptake blockade were also examined. Noradrenaline was measured by h.p.l.c. electrochemical detection. 2 The A1-adenosine receptor agonist, N6-cyclopentyladenosine (CPA; 0.1 − 100 nM) reduced, whereas the A2A-receptor agonist 2-p-(2-carboxyethyl)phenethylamino-5′-N-ethylcarboxamidoadenosine (CGS 21680; 3 − 30 nM) increased evoked noradrenaline overflow. These effects were antagonized by the A1-adenosine receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 20 nM) and the A2-adenosine receptor antagonist, 3,7-dimethyl-1-propargylxanthine (DMPX; 100 nM), respectively. The P2Y-purinoceptor agonist, 2-methylthio-ATP (1 − 100 μm) reduced noradrenaline overflow, an effect prevented by the P2-purinoceptor antagonist, cibacron blue 3GA (100 μm) and suramin (100 μm). 3 Adenosine deaminase (2 u ml−1), DMPX (100 nM) and inhibition of adenosine uptake with S-(p-nitrobenzyl)-6-thioinosine (NBTI; 50 nM) decreased evoked noradrenaline overflow. DPCPX alone did not change noradrenaline overflow but prevented the inhibition caused by NBTI. The P2Y-purinoceptor antagonist, cibacron blue 3GA (100 μm) increased evoked noradrenaline overflow as did suramin, a non-selective P2-antagonist. 4 It is concluded that, in rat tail artery, inhibitory (A1 and P2Y) and facilitatory (A2A) purinoceptors are present and modulate noradrenaline release evoked by electrical stimulation. Endogenous purines tonically modulate noradrenaline release through activation of inhibitory P2Y and facilitatory A2A purinoceptors, whereas a tonic activation of inhibitory A1 purinoceptors seems to be prevented by adenosine uptake.